A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).
Resource
J. Clin. Oncol., 30(15),
Journal
J. Clin. Oncol.
Journal Volume
30
Journal Issue
15
Pages
-
Date Issued
2012
Date
2012
Author(s)
Yau, Thomas Cheung
Sukeepaisarnjaroen, Wattana
Chao, Yee
Yen, Chia-Jui
Lausoontornsiri, Wirote
Chen, Pei-Jer
Sanpajit, Theeranun
Lencioni, Riccardo
Camp, Aaron C.
Cox, Donna S.
Kallender, Howard
Ottesen, Lone Harild
Poon, Ronnie Tung-Ping